Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04800159 · ClinicalTrials.gov registry record · Phase 2

Cannabis Effects on Antiretroviral Therapy Pharmacokinetics and Neurotoxicity

A Phase 2 study of HIV and Cannabis Use, sponsored by University of California, San Diego.

Active
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT04800159 is a Phase 2 study of HIV and Cannabis Use that is active but no longer recruiting, run by University of California, San Diego. The registered enrollment target is 40 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04800159, a Phase 2 study of HIV and Cannabis Use, is active but no longer recruiting, sponsored by University of California, San Diego.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This study will address whether cannabis affects antiretroviral therapy (ART) drug concentrations, mood, and thinking. The project will have two phases. Phase 1 is an observational study, in which 120 people will be assessed to evaluate the effects of chronic cannabis use on ART drug concentrations, mood, and thinking. In Phase 2, the study will administer cannabis (or placebo) to 40 people to examine its acute effects on ART drug concentrations.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG THC Cannabis
  • DRUG CBD Cannabis

Study Locations (1)

California

  • Ucsd Hnrp-Cmcr - San Diego

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2021-02-19
Est. Completion 2026-04-30
Phase Phase 2

Sponsor

University of California, San Diego

775 total trials

What the Registry Record Tells You About NCT04800159

The ClinicalTrials.gov registry entry for NCT04800159 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (91% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT04800159 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04800159 about?

NCT04800159 is a clinical study titled "Cannabis Effects on Antiretroviral Therapy Pharmacokinetics and Neurotoxicity". This study will address whether cannabis affects antiretroviral therapy (ART) drug concentrations, mood, and thinking. The project will have two phases. Phase 1 is an observational study, in which 120 people will be assessed to evaluate the effects of chronic cannabis use on ART drug concentrations,...

What is the current status of trial NCT04800159?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2021-02-19. Estimated completion is 2026-04-30.

What conditions does trial NCT04800159 study?

This clinical trial studies the following conditions: HIV, Cannabis Use.

What interventions are being tested in trial NCT04800159?

The interventions under investigation include: Placebo (DRUG), THC Cannabis (DRUG), CBD Cannabis (DRUG).

Who is sponsoring clinical trial NCT04800159?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04800159 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.